Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours

Trial summary:

A randomised, multi-centre, phase II/III trial to determine whether in patients with mutation positive advanced NSCLC the use of SBRT to ≤ 5 sites of oligoprogressive disease (OPD) with continuation of tyrosine kinase inhibitor (TKI) improves progression-free survival (PFS) compared with continuation of TKI alone

RT QA summary:

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.

QA ProcessQA ActivityRequired for TrialAdditional Details
Pre-AccrualFacility Questionnaire
Outlining Benchmark Case
Planning Benchmark Case
Dummy Run
During AccrualIndividual Case ReviewProspective for all patient
Data collectionAll patients
QA StreamliningCtE, SEP, TRAP, SARON SABR QA programmes for pre-accrual and audit

RTTQA contact:

Chief investigator: Dr Fiona McDonald, Royal Marsden NHS Foundation Trust

Sponsor: Royal Marsden NHS Foundation Trust


Funder: CRUK